AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33276919 — intervention group
Group type: EXPERIMENTAL
Intervention: MIN1 × (Calmin at 1 × concentration)
Number of subjects: 9
Study 33276919 — intervention group
Group type: EXPERIMENTAL
Intervention: MIN2 × (Calmin at 2 × concentration)
Number of subjects: 9
Study 33276919 — intervention group
Group type: COMPARATOR
Intervention: CON (no added Calmin)
Number of subjects: 9
Study 33276919 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect
Number of subjects: 9
Study 34650018 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5% proanthocyanidin (PAC)
Number of subjects: 33
Study 34650018 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% phytosphingosine (PHS)
Number of subjects: 33
Study 34650018 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 33
Study 35410437 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced dementia care management for 6 months, carried out by specialized nurses.
Number of subjects: 465
Study 35410437 — intervention group
Group type: COMPARATOR
Intervention: Routine care for 6 months (waiting-control group).
Number of subjects: 465
Study 33821897 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial use
Number of subjects: 15276
Study 33821897 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial use in residents admitted within 30 days
Number of subjects: 15276
Study 33821897 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial use in residents with central venous catheters
Number of subjects: 15276
Study 33821897 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial use in residents with indwelling urinary catheters
Number of subjects: 15276
Study 33821897 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial use for active infections
Number of subjects: 15276
Study 33821897 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial use for urinary tract infections
Number of subjects: 15276
Study 33821897 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial use for medical prophylaxis
Number of subjects: 15276
Study 33821897 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial use for urinary tract prophylaxis
Number of subjects: 15276
Study 33821897 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 15276
Study 33821897 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics
Number of subjects: 15276
Study 32340423 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario infiltration joint interactive training (SIJIT)
Number of subjects: 118
Study 32340423 — intervention group
Group type: COMPARATOR
Intervention: Routine training (RT)
Number of subjects: 118
Study 32594786 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 2.5 mg/ml
Number of subjects: 12
Study 32594786 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 1.75 mg/ml
Number of subjects: 12
Study 32594786 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 0.375 mg/ml
Number of subjects: 12
Study 32594786 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 12
Study 33393476 — intervention group
Group type: EXPERIMENTAL
Intervention: PanCan model
Number of subjects: 6956
Study 33393476 — intervention group
Group type: COMPARATOR
Intervention: Lung-RADS
Number of subjects: 6956
Study 33393476 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-gap nodules (n=543)
Number of subjects: 6956
Study 33393476 — intervention group
Group type: EXPERIMENTAL
Intervention: PanCan model and Lung-RADS
Number of subjects: 6956
Study 34815165 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders for medication intake (first to seventh postoperative days)
Number of subjects: 0
Study 34815165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 0
Study 33166497 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised dosimetry (≥205 Gy targeted to the index lesion)
Number of subjects: 60
Study 33166497 — intervention group
Group type: COMPARATOR
Intervention: Standard dosimetry (120 ± 20 Gy targeted to the perfused lobe)
Number of subjects: 60
Study 33166497 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised dosimetry
Number of subjects: 60
Study 33166497 — intervention group
Group type: COMPARATOR
Intervention: Standard dosimetry
Number of subjects: 60
Study 32874061 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal formula
Number of subjects: 395
Study 32874061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 35272967 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior rhabdosphincter reconstruction (PRR)
Number of subjects: 152
Study 35272967 — intervention group
Group type: COMPARATOR
Intervention: Control arm (single urethrovesical anastomosis)
Number of subjects: 152
Study 32031973 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program based on the health belief model (HBM) in four 75-min sessions
Number of subjects: 120
Study 32031973 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 34468869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W for up to 35 cycles
Number of subjects: 395
Study 34468869 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (standard-dose)
Number of subjects: 395
Study 33308290 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly debriefing sessions facilitated by a psychotherapist for 3 months
Number of subjects: 200
Study 33308290 — intervention group
Group type: COMPARATOR
Intervention: Control arm without debriefing sessions
Number of subjects: 200
Study 32937016 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 32937016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33864481 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck‐worn position therapy device (PTD)
Number of subjects: 0
Study 33864481 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance (OA)
Number of subjects: 0
Study 32808484 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% calorie-reduced (CR) diet
Number of subjects: 60
Study 32808484 — intervention group
Group type: COMPARATOR
Intervention: Weight-maintaining energy needs (WMEN) diet
Number of subjects: 60
Study 33103499 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabic smartphone application 'My Dear Knee' (n=20)
Number of subjects: 40
Study 33103499 — intervention group
Group type: COMPARATOR
Intervention: Paper hand-outs (control; n=20)
Number of subjects: 40
Study 33223499 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered self-expandable metal stents (CSEMS)
Number of subjects: 0
Study 33223499 — intervention group
Group type: COMPARATOR
Intervention: Uncovered self-expandable metal stents (UCSEMS)
Number of subjects: 0
Study 35001638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg daily)
Number of subjects: 20
Study 35001638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 35001638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 20
Study 33992879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative learner simulation order (LSO)
Number of subjects: 81
Study 35946024 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (n = 20)
Number of subjects: 40
Study 35946024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (n = 20)
Number of subjects: 40
Study 32560746 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa (Pulmozyme®, Roche, Switzerland) administered by aerosol, at a dose of 2500 IU twice daily for 7 consecutive days.
Number of subjects: 100
Study 32560746 — intervention group
Group type: COMPARATOR
Intervention: Usual care without aerosols (control group).
Number of subjects: 100
Study 34318430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar anodal transcranial direct current stimulation (atDCS)
Number of subjects: 20
Study 34318430 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 20
Study 33351479 — intervention group
Group type: EXPERIMENTAL
Intervention: High impact journals (impact factor >3)
Number of subjects: 1044
Study 33351479 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced statistical analysis
Number of subjects: 1044
Study 33351479 — intervention group
Group type: COMPARATOR
Intervention: Medium impact journals (impact factor 1-3)
Number of subjects: 1044
Study 33351479 — intervention group
Group type: COMPARATOR
Intervention: Low impact journals (impact factor <1)
Number of subjects: 1044
Study 32539568 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of decellularized matrix seeded with autologous bone marrow-derived nucleated cells (BMNCs)
Number of subjects: 8
Study 32539568 — intervention group
Group type: COMPARATOR
Intervention: Implantation of decellularized matrix without BMNCs
Number of subjects: 8
Study 35351187 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based intervention (Active 10) supplemented with habit-based behavioural support (two brief telephone/video calls, an information leaflet, and walking planners)
Number of subjects: 0
Study 35351187 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based intervention (Active 10) supplemented with habit-based behavioural support
Number of subjects: 0
Study 35351187 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 0
Study 35351187 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer measured average daily minutes of brisk walking (≥ 100 steps/min)
Number of subjects: 0
Study 36433662 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive collagen peptides (CP) 15 g daily
Number of subjects: 39
Study 36433662 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 39
Study 34494525 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health management
Number of subjects: 295
Study 34494525 — intervention group
Group type: COMPARATOR
Intervention: Traditional management
Number of subjects: 295
Study 32946715 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic procedure for inferring neuronal couplings using a binary statistical model (Ising or generalized McCulloch-Pitts model)
Number of subjects: 0
Study 32946715 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal time bin size determination based on null hypothesis of independent firing
Number of subjects: 0
Study 32946715 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocessing step comparing original estimates with randomized data sets
Number of subjects: 0
Study 33615992 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 0
Study 33615992 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B2
Number of subjects: 0
Study 33615992 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 0
Study 33615992 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 0
Study 33615992 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study 33615992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34535037 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg bid
Number of subjects: 1722
Study 34535037 — intervention group
Group type: COMPARATOR
Intervention: Apixaban 5 mg bid
Number of subjects: 1722
Study 34535037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of apixaban
Number of subjects: 1722
Study 32459597 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab, carboplatin, and paclitaxel (ACP)
Number of subjects: 1187
Study 32459597 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP)
Number of subjects: 1187
Study 32459597 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab, carboplatin, and paclitaxel (BCP)
Number of subjects: 1187
Study 32459597 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms (ACP, ABCP, BCP)
Number of subjects: 1187
Study 32468730 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Sleep Opportunity (ESO) by 90 minutes per night
Number of subjects: 32
Study 32468730 — intervention group
Group type: COMPARATOR
Intervention: Typical Sleep Opportunity (TSO)
Number of subjects: 32
Study 34823952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-fluoro dispersion functionalized silk
Number of subjects: 0
Study 34114630 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical exposure
Number of subjects: 120
Study 34114630 — intervention group
Group type: COMPARATOR
Intervention: Closed surgical exposure
Number of subjects: 120
Study 32386271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar sealing device (BSD) with suture augmentation (4-0 polydioxanone)
Number of subjects: 23
Study 32386271 — intervention group
Group type: COMPARATOR
Intervention: Bipolar sealing device (BSD) without suture augmentation
Number of subjects: 23
Study 33888517 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes diagnosed at age <45 years
Number of subjects: 101080
Study 33888517 — intervention group
Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 101080
Study 33325259 — intervention group
Group type: EXPERIMENTAL
Intervention: HI-FIVES intervention (three weekly facilitated training calls covering five education topics)
Number of subjects: 118
Study 33325259 — intervention group
Group type: EXPERIMENTAL
Intervention: HI-FIVES intervention
Number of subjects: 118
Study 36441735 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model‐Based Intervention (HEBI)
Number of subjects: 284
Study 36441735 — intervention group
Group type: COMPARATOR
Intervention: Health talk on non-communicable disease (Control)
Number of subjects: 284
Study 33836878 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab at 8 mg/kg on day -1 and abatacept at 10 mg/kg on days 0, 7, 14, and 28
Number of subjects: 149
Study 33836878 — intervention group
Group type: EXPERIMENTAL
Intervention: mDLI starting on day 0
Number of subjects: 149
Study 33836878 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort received rabbit ATG at 5 mg/kg total dose
Number of subjects: 149
Study 33836878 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort
Number of subjects: 149
Study 32828682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative application of a penile tourniquet
Number of subjects: 110
Study 32828682 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative application of a penile tourniquet
Number of subjects: 110
Study 36449023 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA with 3-6 cm incision (Group A)
Number of subjects: 730
Study 36449023 — intervention group
Group type: COMPARATOR
Intervention: CEA with >6 cm incision (Group B)
Number of subjects: 730
Study 33020939 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity-based delirium risk index (DRI) derived from 14 comorbidities with weights ranging from 1 to 6.
Number of subjects: 1636007
Study 33020939 — intervention group
Group type: COMPARATOR
Intervention: Charlson-Deyo Comorbidity Index
Number of subjects: 1636007
Study 35618331 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised Patient (SP) role play
Number of subjects: 0
Study 35618331 — intervention group
Group type: COMPARATOR
Intervention: Peer role play
Number of subjects: 0
Study 35618331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SP and Peer)
Number of subjects: 0
Study 33810804 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS) therapy
Number of subjects: 0
Study 33810804 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 0
Study 32218096 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate (ISA) for ≥7 days
Number of subjects: 18
Study 32218096 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate (ISA)
Number of subjects: 18
Study 35138211 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Skill Group (CSG) - focused on acquisition of running, n = 13
Number of subjects: 41
Study 35138211 — intervention group
Group type: COMPARATOR
Intervention: Simple Skill Group (SSG) - focused on locomotion, n = 15
Number of subjects: 41
Study 34159231 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES) applied to four acupoints (Tianshu, Quchi, Zusanli, Shangjuxu), six times a week for 4 weeks
Number of subjects: 60
Study 34159231 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES)
Number of subjects: 60
Study 34159231 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 32412598 — intervention group
Group type: EXPERIMENTAL
Intervention: Theracurmin® (360 mg/day)
Number of subjects: 30
Study 32412598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33450748 — intervention group
Group type: EXPERIMENTAL
Intervention: NSMD + PT
Number of subjects: 42
Study 33450748 — intervention group
Group type: EXPERIMENTAL
Intervention: NSMD + AT
Number of subjects: 42
Study 33450748 — intervention group
Group type: COMPARATOR
Intervention: NSMD alone
Number of subjects: 42
Study 33245618 — intervention group
Group type: EXPERIMENTAL
Intervention: Your Path to Transplant (YPT)
Number of subjects: 802
Study 33245618 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 802
Study 35062886 — intervention group
Group type: EXPERIMENTAL
Intervention: 1–2–3 group receiving 0.25 g/d methylprednisolone intravenously for 3 consecutive days in the 1st‐2nd‐3rd months and oral prednisone 0.5 mg/kg/d for 6 months
Number of subjects: 68
Study 35062886 — intervention group
Group type: COMPARATOR
Intervention: 1–3–5 group receiving the same intravenous methylprednisolone treatment in the 1st‐3rd‐5th months and the same oral prednisone
Number of subjects: 68
Study 35062886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 35062886 — intervention group
Group type: EXPERIMENTAL
Intervention: 1–2–3 group
Number of subjects: 68
Study 35062886 — intervention group
Group type: COMPARATOR
Intervention: 1–3–5 group
Number of subjects: 68
Study 32066290 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized written asthma action plan (WAAP)
Number of subjects: 91
Study 32066290 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge instructions
Number of subjects: 91
Study 33462653 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual zoledronic acid (ZOL) infusion (5 mg) at 1 week, 12 months, and 24 months after surgery
Number of subjects: 154
Study 33462653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 35922187 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete care
Number of subjects: 27192
Study 35922187 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 27192
Study 35922187 — intervention group
Group type: EXPERIMENTAL
Intervention: Third study year
Number of subjects: 27192
Study 33340238 — intervention group
Group type: COMPARATOR
Intervention: TRK‐100STP 240 μg
Number of subjects: 339
Study 33340238 — intervention group
Group type: COMPARATOR
Intervention: TRK‐100STP 120 μg
Number of subjects: 339
Study 32718943 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 180
Study 32718943 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day
Number of subjects: 180
Study 32718943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 35771961 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (offered prostate specific antigen testing every 2 years)
Number of subjects: 20000
Study 35771961 — intervention group
Group type: COMPARATOR
Intervention: Control group (not offered screening)
Number of subjects: 20000
Study 34021033 — intervention group
Group type: COMPARATOR
Intervention: TIL alone
Number of subjects: 18
Study 34021033 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL + DC
Number of subjects: 18
Study 36374501 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estradiol tablet (10 μg/d for 2 weeks and then twice weekly) plus placebo gel (3 times weekly)
Number of subjects: 174
Study 36374501 — intervention group
Group type: COMPARATOR
Intervention: Dual placebo
Number of subjects: 174
Study 33016987 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Basic Care (ABC) family education combined with Head Start asthma education
Number of subjects: 398
Study 33016987 — intervention group
Group type: COMPARATOR
Intervention: Head Start asthma education alone
Number of subjects: 398
Study 33492523 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 96
Study 33492523 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 96
Study 32272518 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA) diluted with normal saline (1:2) injected subdermally
Number of subjects: 20
Study 32272518 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfocused ultrasound with visualization (MFU-V)
Number of subjects: 20
Study 32272518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CaHA and MFU-V
Number of subjects: 20
Study 35074830 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic bladder advice (voiding and drinking according to a strict schedule and instructions regarding toilet posture)
Number of subjects: 60
Study 35074830 — intervention group
Group type: EXPERIMENTAL
Intervention: Enuresis alarm therapy
Number of subjects: 60
Study 35074830 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 60
Study 33214022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram incorporating five feature variables: PCI timing after hospitalization, ejection fraction (EF), high-sensitive troponin T (hsTnT) score, infection, and estimated glomerular filtration rate (eGFR).
Number of subjects: 503
Study 33214022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram with five variables for predicting VTA risk.
Number of subjects: 503
Study 32278339 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-filled composite resins with etch-and-rinse, self-etch, or selective-etch protocols
Number of subjects: 96
Study 32278339 — intervention group
Group type: COMPARATOR
Intervention: Conventional composites with etch-and-rinse, self-etch, or selective-etch protocols
Number of subjects: 96